Syneos Health (NASDAQ:SYNH) is scheduled to post its quarterly earnings results after the market closes on Monday, March 18th. Analysts expect Syneos Health to post earnings of $0.73 per share for the quarter.
NASDAQ SYNH opened at $41.60 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.97 and a current ratio of 0.97. Syneos Health has a 12 month low of $34.40 and a 12 month high of $56.34. The company has a market capitalization of $4.29 billion, a P/E ratio of 21.44, a price-to-earnings-growth ratio of 1.19 and a beta of 1.41.
In other news, General Counsel Jonathan Olefson purchased 750 shares of the business’s stock in a transaction dated Monday, December 17th. The shares were acquired at an average price of $41.27 per share, for a total transaction of $30,952.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alistair Macdonald sold 8,143 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $53.00, for a total transaction of $431,579.00. The disclosure for this sale can be found here. 0.57% of the stock is owned by insiders.
A number of analysts recently commented on the stock. ValuEngine upgraded shares of Syneos Health from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Zacks Investment Research upgraded shares of Syneos Health from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Tuesday, December 18th. SunTrust Banks dropped their target price on shares of Syneos Health to $55.00 and set a “buy” rating on the stock in a report on Wednesday, December 19th. Finally, Robert W. Baird set a $60.00 target price on shares of Syneos Health and gave the stock a “buy” rating in a report on Tuesday, January 8th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Syneos Health has an average rating of “Buy” and a consensus price target of $53.44.
COPYRIGHT VIOLATION NOTICE: “Syneos Health (SYNH) Set to Announce Earnings on Monday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/03/15/syneos-health-synh-set-to-announce-earnings-on-monday.html.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: How to use beta for portfolio diversification
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.